OKYO Pharma Limited, located in the UK, creates medications for patients with inflammatory eye diseases and ocular pain. They are best known for their lead product OK-101, which helps those who suffer from dry eye disease. Additionally, the company is working on developing OK-201, which is a preclinical analogue used to treat neuropathic ocular pain.